105 related articles for article (PubMed ID: 28485692)
21. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.
Naruto K; Kawaoka T; Yamasaki S; Kosaka M; Shirane Y; Johira Y; Yano S; Amioka K; Ogawa Y; Yoshikawa Y; Yamaoka K; Uchikawa S; Fujino H; Ono A; Fujii Y; Nakahara T; Murakami E; Miki D; Tsuge M; Oka S
Yonago Acta Med; 2023 Nov; 66(4):422-431. PubMed ID: 38028262
[TBL] [Abstract][Full Text] [Related]
22. Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal.
Machak GN; Bruland ØS; Romanova TN; Kovalev AV
J Bone Oncol; 2024 Apr; 45():100596. PubMed ID: 38545297
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of cardiovascular outpatient rehabilitation care and spa treatment care for patients with heart disease.
Gajdoš O; Kamenský V; Doskočilová K; Caithamlová M; Kubátová I
Cost Eff Resour Alloc; 2020; 18():39. PubMed ID: 33013203
[TBL] [Abstract][Full Text] [Related]
24. The abolition of user charges and the demand for ambulatory visits: evidence from the Czech Republic.
Votapkova J; Zilova P
Health Econ Rev; 2016 Dec; 6(1):29. PubMed ID: 27422120
[TBL] [Abstract][Full Text] [Related]
25. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
[TBL] [Abstract][Full Text] [Related]
27. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Schröder J; Fietz T; Köhler A; Petersen V; Tesch H; Spring L; Fleitz A; Jänicke M; Marschner N;
Eur J Cancer; 2017 Jul; 79():139-148. PubMed ID: 28494404
[TBL] [Abstract][Full Text] [Related]
28. The role of bone-targeted therapies for prostate cancer in 2017.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2017 Sep; 11(3):216-224. PubMed ID: 28644302
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates or denosumab discontinuation and risk of fractures.
Anastasilakis AD; Yavropoulou MP; Makras P
Maturitas; 2017 Aug; 102():75. PubMed ID: 28495014
[No Abstract] [Full Text] [Related]
30. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Qaseem A; Forciea MA; McLean RM; Denberg TD; ; Barry MJ; Cooke M; Fitterman N; Harris RP; Humphrey LL; Kansagara D; McLean RM; Mir TP; Schünemann HJ
Ann Intern Med; 2017 Jun; 166(11):818-839. PubMed ID: 28492856
[TBL] [Abstract][Full Text] [Related]
31. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.
Parente P; Ng S; Parnis F; Guminski A; Gurney H
Asia Pac J Clin Oncol; 2017 Dec; 13(6):391-399. PubMed ID: 28488360
[TBL] [Abstract][Full Text] [Related]
32. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
33. The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials.
Zhang Z; Pu F; Shao Z
J Bone Oncol; 2017 Nov; 9():21-24. PubMed ID: 29123990
[TBL] [Abstract][Full Text] [Related]
34. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
Terpos E; Jamotte A; Christodoulopoulou A; Campioni M; Bhowmik D; Kennedy L; Willenbacher W
J Med Econ; 2019 Aug; 22(8):766-776. PubMed ID: 30969797
[No Abstract] [Full Text] [Related]
35. Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.
Al Farii H; Frazer A; Farahdel L; AlFayyadh F; Turcotte R
J Am Acad Orthop Surg Glob Res Rev; 2020 Aug; 4(8):e20.00045. PubMed ID: 32769706
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
[TBL] [Abstract][Full Text] [Related]
37. Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
Chen S; Han Y; Ouyang Q; Lu J; Zhang Q; Yang S; Wang J; Huang H; Liu H; Shao Z; Li H; Chen Z; Sun S; Geng C; Lu J; Sun J; Wang J; Xu B
BMC Cancer; 2021 Mar; 21(1):341. PubMed ID: 33789616
[TBL] [Abstract][Full Text] [Related]
38. Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease.
Pai SM; Yamada H
Clin Pharmacol Drug Dev; 2021 May; 10(5):463-470. PubMed ID: 33788422
[TBL] [Abstract][Full Text] [Related]
39. SEOM clinical guidelines for anaemia treatment in cancer patients (2020).
Escobar Álvarez Y; de Las Peñas Bataller R; Perez Altozano J; Ros Martínez S; Sabino Álvarez A; Blasco Cordellat A; Brozos Vázquez E; Corral Jaime J; García Escobar I; Beato Zambrano C
Clin Transl Oncol; 2021 May; 23(5):931-939. PubMed ID: 33768441
[TBL] [Abstract][Full Text] [Related]
40. Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea.
Cheon J; Im HS; Shin HJ; Kim I; Lee WS; Lee KH; Park SK; Kim MK; Choi UJ; Kim JH; Lee I; Jo JC
Support Care Cancer; 2021 Sep; 29(9):5383-5390. PubMed ID: 33683460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
